VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. The company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome.